A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study in Healthy Men to Investigate the Effect of a Single Dose of ASP2151 on the Pharmacokinetics of Montelukast

Trial Profile

A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study in Healthy Men to Investigate the Effect of a Single Dose of ASP2151 on the Pharmacokinetics of Montelukast

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Amenamevir (Primary) ; Montelukast
  • Indications Herpes simplex virus infections; Herpes zoster
  • Focus Pharmacokinetics
  • Sponsors Maruho
  • Most Recent Events

    • 17 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 05 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015, according to to ClinicalTrials.gov record.
    • 05 Jun 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jun 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top